<p>Propanc Biopharma Inc. announced the filing of a new provisional patent application for methods of producing trypsinogen and chymotrypsinogen, utilizing an optimized expression system to create a fully synthetic recombinant version of PRP, aimed at treating and preventing metastatic cancer from solid tumors. The company highlights that this synthetic approach could offer significant advantages, including longer shelf life without refrigeration and consistent quality without relying on animal sources. These developments are part of Propanc’s ongoing efforts to expand its intellectual property portfolio and develop novel cancer therapies. The announcement pertains to the patent filing and does not specify the presentation of scientific research results at this time. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9628349) on January 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

PPCB

SBIO

<p>Propanc Biopharma Inc. has filed a new provisional patent application for producing synthetic enzymes, trypsinogen and chymotrypsinogen, aimed at treating metastatic cancer from solid tumors. This synthetic approach promises advantages like longer shelf life and consistent quality without animal sources. The announcement focuses on the patent filing and does not include scientific research results at this time.</p>

Propanc Biopharma Develops Synthetic Enzyme Therapy for Metastatic Cancer